ArticleTranslational cancer research2026
URGCP promotes osteosarcoma progression by regulating the ESCRT-III subunit CHMP4B.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteosarcoma (OS) is the most common primary malignant bone tumor in adolescents, with a persistently poor prognosis due to limited effective therapeutic targets. Identifying key oncogenic drivers and their regulatory networks is critical for developing novel targeted therapies to improve clinical outcomes. In this study, we aimed to investigate the expression pattern, diagnostic value, and functional role of upregulator of cell proliferation (URGCP) in OS, as well as to elucidate its downstream molecular mechanism, specifically focusing on the URGCP-CHMP4B regulatory axis. Methods: We conducted a bioinformatics analysis of public datasets (Gene Expression Omnibus) to identify the dysregulation and diagnostic value of Results: Bioinformatics analyses revealed that Conclusions: Our study identifies URGCP as an oncoprotein in OS that exerts its tumor-promoting effects, at least in part, by positively regulating CHMP4B. The URGCP-CHMP4B axis represents a potential therapeutic target for OS treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.